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Introduction. Rapidly growing prevalence of cardiovascular disease is a major threat for the developed as well as developing
world warranting urgent need of intervention. Complementary and alternative medicines are gaining popularity among general
population because of their safety profile and easy administration. Garlic, in particular, is considered to be one of the best
disease-preventive foods because of its potent and widespread effects. This study was done to find out the role of garlic usage
in cardiovascular disease prevention. Methodology. Major databases including Google, PubMed, MEDLINE, and Cochrane library
view were used for the literature search. Clinical trials conducted on humans assessing role of garlic usage in cardiovascular disease
prevention and the possible mechanisms responsible for such therapeutic actions were assessed. Results. Various clinical trials and
meta-analyses conducted have shown positive impact of garlic in cardiovascular-disease prevention especially its effects on lipid
levels; however, some contradictory results are also reported. Similarly, its effects on hypertension control, and platelet are also
mild with limited data availability. The possible reason for these inconsistent results is the difference in preparations with diverse
composition, variations in sulphur content present in different garlic preparations used, and methodological variations in subject
recruitment, duration of study, dietary control and so forth. Conclusion. Garlic can be used as an adjuvant with lipid-lowering drugs
for control of lipids, however, its role as a main therapeutic agent cannot be recommended and it is suggested that more metaanalyses using standardized preparations with a close watch on methodological shortfalls should be conducted to prove its role.

1. Introduction
The epidemic of cardiovascular disease is growing at an
alarming pace throughout the world [1]. It is recognized
as one of the leading causes of mortality worldwide causing more than 80% of deaths in low- and middle-income
countries [2]. Cardiovascular disease refers to spectrum of
illnesses that includes heart disease, vascular diseases of the
brain, kidney, and peripheral arterial disease [3]. According
to an estimate by World Health Organization, approximately
17.3 million people died from CVDs in 2008, representing
30% of all global deaths. Out of these deaths, 7.3 million
occurred secondary to coronary heart disease and 6.2 million
as a consequence of stroke [2]. It is anticipated that by 2020
cardiovascular diseases are predicted to be the major cause of
morbidity and mortality in most developing nations around
the globe [4]. Atherosclerosis and hypertension are measured

as the major risk factor along with smoking, obesity, and sedentary life styles leading to increasing trend of this major
threat [5].
Today, in this era of rapid advancement in medical technology, herbal or botanical preparations, commonly referred
to as complementary and alternate medicine (CAM),
approaches have gained lots of popularity in terms of health
care maintenance, and a large number of population in the
developing as well as developed world prefer to use (CAM)
as a source of curative and preventive remedy for various illnesses [6, 7]. CAM is defined as a group of diverse medical
and health systems practices and products that are not
generally considered as part of conventional medicine [8].
According to 2007 National Health Interview Survey (NHIS)
report, approximately 38% of US adults and 12% of children are using CAM in the past 12 months; lifetime prevalence
of CAM use in the United States and worldwide has
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increased steadily since 1950 (9.10). Most common types
of CAM therapies used were natural products, such as fish
oil/omega 3, glucosamine, Echinacea, and flaxseed (17.7%),
deep breathing (12.7%), meditation (9.4%), chiropractic and
osteopathic (8.6%), and massage (8.3%), followed by yoga,
diet-based therapies, progressive relaxation, guided imagery,
and homeopathic treatment [9].
Among all these remedies, plants-based functional foods
have gained lots of recognition throughout the world and it
is believed that these natural substances have the potential to
reduce the detrimental effect of a number of cardiovascular
diseases and associated risk factors [10]. The probable reason
for this rising trend is skeptic approach of general public
towards conventional medicine due to fear of more side
effects and increasing cost. This fact was further driven by the
belief of increased safety profile and easy availability of plantbased natural products in comparison to orthodox medicine.
Garlic has been used as a therapeutic agent for many illnesses
over centuries as evident from various studies; however, its
role in cardiovascular disease prevention is still questionable.
This review was done to find out the efficacy of garlic in
cardiovascular disease prevention through evidence-based
approach by analyzing clinical trials and systematic review in
the above mentioned area.

2. Garlic as a Potential Herb
Garlic (Allium sativum) has played an important dietary as
well as medicinal role in human history. The role of garlic
(Allium sativum) as a potential herb has been acknowledged
for over 5000 years. Garlic and its various preparations are
being readily consumed as a food and spice by various cultures for centuries [11]. It was also documented as a choice of
medical therapy to combat many diseases among Egyptians
[12]. Similarly, it is also considered as an imperative part
of Indian traditional medicine, that is, Ayurveda, Tibbi and
Unani, and so forth. In addition, it is also claimed to possess beneficial effects for the prevention of various aspects
of cardiovascular disease including hypertension and dyslipidemia [13].

3. Garlic Composition
Garlic is available in many forms among these raw garlic and
aqueous extract preparation is used more frequently. Allicin
is the principal bioactive compound present in garlic and
primarily contains sulphur as a main constituent which on
break down gives garlic its characteristic odor. It is produced
as a result of activation of alliinase enzyme after crushing or
chopping of raw garlic. The enzyme Allinase is inactivated by
heat leaving behind alliin as the main constituent present in
the water extract of heat-treated garlic. The composition of
garlic powder which is produced after dehydration and crushing is the same as raw garlic and alliinase activity is preserved;
however, caution needs to be taken regarding temperature
regulation as Allinase is inactivated if temperature exceeds
beyond 60∘ C. Apart from Alliin, other important sulfurcontaining compounds present in garlic homogenate include
allyl methyl thiosulfonate, 1-propenyl allyl thiosulfonate, and
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𝛾-L-glutamyl-S-alkyl-L-cysteine. On an average, a garlic bulb
contains up to 0.9% g-glutamylcysteines and up to 1.8% alliin
[14].

4. AGE Preparation
Another important and extensively studied garlic preparation
is aged garlic extract (AGE). This form is produced by storage
of sliced raw garlic in 15–20% ethanol for 20 months. This process of storage leads to alteration in composition of the garlic
extract, the odorous, harsh, and irritating compounds in
garlic are converted naturally into stable and safe sulfur compounds with substantial loss of allicin activity and increased
activity of new compounds, like S-allylcysteine (SAC), Sallylmercaptocysteine, and allixin [15]. SAC can be used for
standardization because of its bioavailability property.

5. Garlic Oil
Garlic oil another important preparation is produced as a
result of distillation process of raw garlic. Garlic essential oil
is obtained by steam distillation of garlic. The essential oil
content of garlic cloves is 0.2–0.5% and consists of a variety
of sulfides, such as diallyl disulphide (DADS) and diallyl
trisulfide (DATS) [16, 17]. All the water soluble contents
including allicin are completely eliminated from the oil. Oil
macerates were originally developed for use as condiments.
Oil macerate products are made of encapsulated mixtures of
whole garlic cloves ground into vegetable oil. This preparation
contains allicin-decomposed compounds such as dithiins,
ajoene and sulfides, residual amounts of alliin, and other
constituents in garlic [16].

6. Garlic Powder
Garlic powder is primarily used as a flavoring agent for condiments and processed foods. Garlic cloves are sliced or
crushed, dried, and ground into powder. The composition of
garlic powder is the same as that of raw garlic; however, the
proportions and amounts of various constituents differ significantly; that is, average content of alliin present in garlic is
0.8% however, raw garlic contains around 3.7 mg/gm of alliin
[18].

7. Garlic and Cardiovascular
Disease Prevention
Cardiovascular disease is one of the leading cause of morbidity and mortality worldwide. Role of garlic in cardiovascular
disease prevention has been a topic of concerns for many
years. Various observational and experimental studies done
on animals showed encouraging results. However, these
claimed benefits were not supported by evidence-based clinical studies. This fact prompted many researchers to conduct
clinical trials in order to explore and address the efficacy and
association of garlic with various aspects of cardiovascular
disease.
In recent years, garlic has been a focus of attention
because of its potential role in the prevention of various
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aspects of cardiovascular disease [19, 20]. Evidence from
numerous studies suggests that garlic works through various
mechanisms to achieve this favorable effect including reduction of serum lipids and blood pressure levels, inhibition of
platelet aggregation, and increasing fibrinolytic antioxidant
activity. Majority of the studies reported have shown positive
impact; however, few numbers of contradictory studies have
[21, 22] made the role of garlic questionable especially with
regards to its effects on lipid levels and hypertension. This
review will critically examine the current scientific literature
concerning claims of cardiovascular benefits from regular
consumption of garlic or its preparations and the possible
mechanisms responsible for such therapeutic actions.

8. Methodology
This paper is based on a literature search of clinical trials
and systematic reviews published from 1990–2012 to see the
effect of Garlic on cardiovascular disease prevention. For
this purpose multiple search engines including MEDLINE,
PubMed, Google, and Cochrane library were used. Search
was validated by other author.

9. Inclusion Criteria
All human studies (clinical trials) in English assessing the
effect of garlic on cardiovascular disease prevention among
patients with dyslipidemia, hypertension, or cardiovascular
disease were included.

10. Exclusion Criteria
Studies conducted among animals were excluded. Theses, dissertations, unpublished data, and letter to editor were also excluded.
A number of keywords were used for data searching
including garlic and cardiovascular disease clinical trial,
garlic hypertension and dyslipidemia, platelet aggregation,
and clinical trial.

11. Garlic Role in Dyslipidemia
Dyslipidemia is documented as a major risk factor responsible for the development of atherosclerosis and cardiovascular disease [23]. Lipid abnormalities include high LDLC (low-density lipoprotein cholesterol), high triglycerides
and low HDL-C (high-density lipoproteins cholesterol) levels. Cholesterol present in 𝛽-lipoprotein (LDL) and pre-Blipoprotein gets deposited into the blood vessels, while 𝛼lipoprotein (HDL) helps to reduce serum cholesterol [24].
Impact of garlic on elevated lipid level is the most widely studied outcome of interest as evident from Table 1. Considerable
evidence from the literature supports the invaluable role of
garlic in the treatment of hypercholesterolemia through inhibition of cholestrol biosynthesis in the liver and also by inhibition of oxidation of low-density lipoproteins [25]. Dietary
approach is the initial step in the management of dyslipidemia, and many people with dyslipidemia are using garlic as
an alternative medicine to normalize their raised lipid levels.
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A number of randomized, controlled trials were carried
out to see the effect of different preparation of garlic on lipid
levels. In the early 1980s, a trial done [19] on human subject after ingestion of 40 gm garlic demonstrated significant
reduction in total cholestrol and triglyceride levels. Similarly,
one study conducted by Mader [20] in 1990 among patients
suffering from dyslipidemia over a period of 16 weeks using
800 mg of garlic (standardized to 1.3% of Alliin) showed
12% reduction in serum cholestrol levels and 17% reduction
in triglyceride levels in comparison to placebo; however, it
was also noticed that the greatest cholesterol-lowering effects
were seen in patients with initial total cholesterol values
between 250 and 300 mg/dL. The results of this trial were
somewhat contradicted by findings of a trial by Saradeth et
al. [26] where 600 mg of dried garlic powder (Kwai, Lichwer
standardized to 1.3% alliin) was given to healthy patients with
normal lipid levels over a period of 10 weeks. There was
a significant reduction in total cholestrol and triglycerides
levels confirming the fact that it can induce changes in
blood lipids, even if these variables had been normal to
start with Similarly another trial by Gadkari and Joshi on
healthy medical students after consumption of 10 gm raw
garlic showed significant reduction in serum cholesterol and
increase in clotting time and fibrinolytic activity [27].
Clinical trials using different types of garlic preparations
in hypercholesterolemia patients have demonstrated debatable results, and it was assumed that these discrepancies may
have resulted due to the differences of the composition of
garlic preparations and the response they may induce. This
fact was well proven by a study done by Sobenin et al. [28]
in which patients with mildly raised lipid levels were given
garlic powder tablets (allicor) containing 600 mg of garlic
content. A moderate decrease in lipid levels was seen (7.6%
decrease in cholesterol; 11.7% decrease in LDL levels); in addition, a substantial rise in HDL level 11.5% was also noticed. It
was assumed that this hypocholesterolemic action of garlic
preparations may be due to the use of a time-released form
of garlic powder tablets. Similarly, a commonly used preparation of garlic in the form of AGE extract of 7.2 gm daily for
6 months also showed beneficial effects on the lipid profile
of moderately hypercholesterolemia subjects. There was an
overall 6.1% decrease in cholestrol levels and 4% decrease in
LDL levels noticed thus confirming its efficacy [29].
Another randomized placebo control trial using 5 gm of
raw garlic on patients with mildly raised lipids was used for
42 days and demonstrated significant reduction in cholestrol
and triglyceride levels with a rise in HDL levels; however,
these effects were not sustainable and returned to baseline
levels as soon as the garlic use was withdrawn. This suggested
that garlic consumption alone can decrease serum lipids in
patients with mildly raised lipid levels; however, it cannot be
used as the main therapeutic agent for hyperlipidemia [30].
Dyslipidemia refers to increase in cholestrol, triglycerides, and LDL levels with a decrease in HDL level (below
40 mg). It was expected that apart from decreasing cholestrol,
LDL and triglycerides levels, garlic also has an impact on
low HDL which was further established by a trial conducted
on healthy individuals with a decreased HDL levels below
10 mg at baseline. They were given high-fat diet followed
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Table 1: Effects of garlic on lipid levels.

Study

Type

Randomized,
Mader, (1990) [20] placebo-controlled
trial
Gadkari and Joshi, Randomized
(1991) [27]
control trial
Rotzsch et al.,
(1992) [31]
Saradeth et al.,
(1994) [26]

Steiner et al.,
(1996) [29]

Randomized,
placebo-controlled,
double-blind trial
Randomized
double-blind study,
placebo-controlled
trial
Double-blind
crossover trial

Randomized,
double-blind,
placebo-control
trial
Double-blind,
Berthold et al.,
randomized,
(1998) [39]
placebo-controlled
trial
Randomized,
Satitvipawee et al., double-blind,
(2003) [37]
placebo-controlled
trial
Isaacsohn et al.,
(1998) [38]

Target

Duration
of Rx

Dose

Hyperlipidemic

12 weeks

800 mg garlic
powder

130/131

Dec in T. chol level—12%,
TG level—17%

Normal individuals

2 months

10 gm of raw
garlic

25/25

Dec T. chol, increase
clotting time, and
fibrinolytic activity

Healthy
individuals with
low HDL

6 weeks

900 mg garlic
powder

12/12

Dec TG levels and increase
HDL levels

Healthy
individuals with
normal lipid levels

15 weeks

600 mg dried
garlic powder

34/34

Hyperlipidemic

11 months

7.2 g aged garlic

20/21

Hyperlipidemic

12 weeks

900 mg garlic
powder (Kwai)

28/22

No change in lipid levels
noticed

Hyperlipidemic

12 weeks

10 mg garlic oil

12/13

No change in lipids or
lipoproteins levels noticed

Hyperlipidemic

4 weeks/12
weeks

Garlic extract

70/76

No dec in T. chol, DL, TG,
and HDL levels noticed

30

21/21

Mahmoodi et al.,
(2006) [30]

Clinical trial

Hyperlipidemic

42 days

Raw garlic 5 gm
twice daily

Sobenin et al.,
(2008) [28]

Double blinded
placebo controlled

Hyperlipidemic

12 weeks

Allicor
(600 mg daily)

Case/control Outcome

T. chol dec from 223 to
214 mg/dL
TG dec from 124 to
118 mg/dL
Dec T. chol 6.1%, dec LDL
4%, systolic BP 5.5% dec,
and modest dec in diastolic
Bp noticed

Dec T. chol, dec LDL, dec
TG, increase HDL level
Reversed after stopping of
garlic
T. chol 7.6% dec, LDL 11.8%,
and HDL inc 11.5%

T. chol: total cholesterol, HDL: high-density lipoprotein, TG: triglyceride, LDL: low-density lipoprotein, and VLDL: very low-density lipoprotein.

by garlic powder preparation (Sapec, Kwai) of 900 mg daily
for 6 weeks. A significant decrease in triglyceride levels was
observed in the treatment group in comparison to placebo
group with a significant rise in HDL levels above baseline
[31]. Similarly another study reported that 3 g of fresh garlic
(1 clove) daily for 16 weeks had a 21% decrease in cholesterol
levels [32].
Despite the existence of various clinical trials, the role of
garlic in treating dyslipidemia is still debatable. In order to
address this query a various meta-analyses were also conducted. A meta-analyses done by Silagy and Neil studied 16
trials among 952 patients using garlic, both in powder and
nonpowder form. There was an overall reduction in cholestrol level seen that is, 8% with powdered form while
15% with nonpowder preparations. Significant lowering of
serum triglyceride was also noticed, while HDL level remains
unchanged [33].

Similarly, another meta-analyses by Warshafsky et al.
among patients with cholestrol levels greater than 200 mg
showed significant reduction in total cholesterol levels. It was
suggested that garlic in an amount approximately one half to
one clove per day is effective in reducing cholesterol levels by
about 9% [34].
A recent meta-analyses conducted by Zeng et al. in 2012
clearly illustrated that garlic therapy is more effective if used
for a long term with higher baseline total cholestrol levels;
they also concluded that garlic powder and aged garlic extract
were more effective in reducing serum TC levels, while garlic
oil was more effective in lowering serum TG levels [35]. A
trial comparing garlic with a commercial lipid-lowering drug
(bezafibrate) found them to be equally effective in decreasing
lipids to a statistically significant extent [36].
There were few clinical trials which did not show any
effects on lipid levels. A trial done by Satitvipawee et al. for
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Table 2: Effect of garlic on blood pressure levels.
Study
Zhang et al.,
(2001) [48]
Dhawan and Jain,
(2004) [49]
Capraz et al.,
(2007) [55]
Duda et al.,
(2008) [51]
Ried et al.,
(2010) [50]
Ried et al.,
(2013) [53]

Type
Parallel-controlled
trial
Not placebo
controlled
Randomized
placebo control
trial
Prospective and
uncontrolled
clinical study
Randomized
placebo control
trial
Double-blind,
randomized
placebo-controlled,
dose-response trial

Target

Duration of Rx

Case/control Outcome
Dose
Distilled garlic oil
14/13
Garlic oil lowers SBP and DBP
12.3 mg/d
Garlic pearls
Dec Bp, dec ox-LDL, and
20/20
250 mg
8-iso-PGF2alpha levels

Hypertensives

16 weeks

Hypertensives

2 months

Hypertensives

70 minutes

Rw garlic, Garlic
tablets

25/25/25

Hypertensives

30 days

Antihypertensive
drug + Garlic
capsules

38/32

Dec total lipids and lipid
peroxidation noticed

Hypertensives

12 weeks

960 mg AGE

25/25

SBP—10.2 ± 4.3 mmHg dec

Hypertensives

12 weeks

Aged garlic
240/480/960 mg

26/26/27

SBP—11.8 ± 5.4 mmHg, (2
capsule) 7.4 ± 4.1 mmHg (4
capsule)

No effects on BP levels

T. chol: total cholesterol, HDL: high density lipoprotein, TG: triglyceride, LDL: low-density lipoprotein, VLDL: very low-density lipoprotein, 8-OHdG: (8Hydroxy-2 -deoxyguanosine), and 8-iso-PGF2alpha: (8-iso-Prostaglandin F2alpha).

a period of 12 weeks using 5.6 mg/tablet garlic tablets showed
no significant improvement in lipids levels [37].
An RCT in which 900 mg garlic in the form of tablets
(Kwai) was given daily to patients with hypercholesterolemia
showed no significant change in lipid levels in comparison
to placebo group [38]. Similarly, in other trial steams distilled
garlic oil in a quantity of 5 mg twice daily for 12 weeks showed
no influence on lipid levels [39]. A trial with garlic usage in
the form of dried form in a dose of 600 mg to 1500 mg did
not show any effects suggesting that dried preparation in the
dosage studied were ineffective in reducing lipid levels [40].
Similarly, a meta-analyses by Khoo and Aziz also showed
insignificant outcomes [41].
One trial of garlic extract treatment in children with
hypercholesterolemia found no adverse effects and no significant beneficial effect on lipid levels [42].
Clinical investigations exploring the effects of garlic
and its various preparations in hypercholesterolemia have
demonstrated somewhat contradictory results. The diverse
composition and amount of active sulfur compounds of
different garlic preparations used in various trials might be
responsible for the above mentioned inconsistent findings.
Other factors like subject recruitment, duration of study,
dietary control, lifestyle, and methods of lipid analyses may
also have an influence. These findings emphasize the need for
standardization of garlic preparations in order to reach to a
valid conclusion.

12. Effects of Garlic on Hypertension
Hypertension is an important risk factor for leading to
cardiovascular disease. Currently, it affects 1 billion people
worldwide, and this number is expected to rise to 1.6 billion
by 2025 [43, 44]. Garlic regular consumption has shown
some association with blood pressure control. Blood pressure
reducing properties of garlic are related with the hydrogen

sulphide production [45] and allicin content liberated from
alliin and the enzyme alliinase [46] which is assumed to possess angiotensin II inhibiting and vasodilating effects. Garlic
is used as a treatment remedy by many people worldwide
to control blood pressure. According to one survey, approximately 29% of people are using garlic for their blood pressure
control [47].
The antihypertensive effects of garlic have been studied,
but the remaining controversial various studies done showed
controversial results as evident from Table 2. Clinical trial
done by Zhang et al. consuming garlic oil in hypertensive
patients over the 16-week period showed significant results
[48]. A trial using garlic pearls containing 250 mg of garlic
among hypertensive patients for 2 months demonstrated
decrease in blood pressure level and also showed decrease in
biomarkers responsible for oxidative stress in blood (plasmaoxidized LDL, plasma, and urinary concentration of 8-isoProstaglandin F2alpha) ultimately decreasing the risk of
cardiovascular disease [49].
Majority of patients used garlic as a remedy for prevention
from dyslipidemia and hypertension various illnesses. An
RCT conducted by Ried et al. on patients with uncontrolled
blood pressure used AGE preparation of 900 mg garlic containing (2.4 mg salicystine) for 12 weeks and concluded that
significant reduction in blood pressure level was noted only
among patients who had blood pressure values of more than
140 mm Hg at baseline [50] suggesting that its role in primary
prevention is questionable.
Another trial by Duda et al. assessed the role of garlic on
blood pressure and lipids levels and concluded that garlic can
be used as a tentative treatment along with antihypertensive
drug because of its positive effect on lipid levels and antioxidant properties [51].
Few meta-analyses were also done to see the efficacy.
In 1994, a meta-analyses assessed the effect of garlic on
hypertension, among which three trials showed significant
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Table 3: Effect of garlic on cardiovascular disease.

Study
Bordia et al.,
(1998) [63]
Sobenin et al.,
(2010) [71]

Type

Target

Placebo control Coronary artery
trial
disease patients
Randomized
control trial

Coronary artery
disease patients

Duration of
treatment

Dose

3 months

1 gm garlic
(capsules)

Oral

30/30

1 year

Time-released
garlic powder

Oral

26/25

Route Case/control Outcome
Dec T. chol and TG,
increase HDL level, and
no effect on fibrinogen
and glucose level
Dec LDL—32.9 mg/dL
in males, 27.3 mg/dL in
females

T. chol: total cholesterol, HDL: high-density lipoprotein, TG triglyceride, LDL: low-density lipoprotein.

reductions in systolic blood pressure (7.7 mm Hg greater
reduction), and four trials showed reductions in diastolic
blood pressure (5 mm Hg greater reduction) in comparison
to placebo [52].
A meta-analyses conducted by Ried et al. showed significant results with decrease in systolic blood pressure of about
16.3 mm Hg and diastolic blood pressure of about 9.3 mm Hg
in comparison to placebo group; however, these effects were
only observed in patient having systolic blood pressure values
more than 140 mm Hg [53].
Another meta-analyses done concluded that garlic
reduces mean supine systolic and diastolic blood pressure by
approximately 10–12 mm Hg and 6–9 mm Hg, respectively,
over and above the effect of placebo, but the confidence intervals for these effect estimates are not clear cut, and this difference in blood pressure reduction may be due to subjective
variation in blood pressure measurements suggesting more
clinical trials [54].
Few trials done by Capraz et al. and Pittler and Ernst
showed insignificant results [55, 56]. Similarly a meta-analyses done by Simons et al. also showed insignificant results
with no effects on blood pressure levels and concluded that
the effect of garlic on blood pressure cannot be established
[57].
To ascertain the effectiveness of garlic in blood pressure
reduction, very few studies are available which have shown
small positive effects, insufficient to draw any conclusions.
Information gathered from the previous meta-analyses is also
inconclusive due to methodological shortcomings. Therefore,
in our view, use of garlic cannot be recommended as antihypertensive advice for hypertensive patients in daily practice.
Further, meta-analyses are required to prove its efficacy.

13. Effects on Platelets and
Fibrinolytic Activity
Garlic has a beneficial effect on platelet adhesion or aggregation, a potential risk factor for cardiovascular disease. The
self-condensation products of allicin and ajeones are said to
have antithrombotic action, in addition to its potential effect
in the inhibition of platelet aggregation [58] 23. Dissolution
of clots and thrombi through fibrinolysis is also improved by
garlic.
A number of trials have been conducted to find out the
usefulness of garlic or its preparation against platelets. A
trial by Rahman and Billington reported that garlic causes

inhibition of platelet aggregation by various mechanisms
including inhibition of cyclooxygenase activity leading to
thromboxane A2 formation, by suppressing mobilization
of calcium into the platelets, and by increasing levels of
messengers (cAMP and cGMP) with in the platelets. It also
exhibits strong antioxidant property by increasing production of platelet-derived NO. Simultaneously, it also reduces
the ability of platelets to bind to fibrinogen, thus overall
resulting in inhibition of platelet aggregations and enhance
fibrinolytic activity [59].
This fact was further confirmed by a trial by Allison et al.
which showed that AGE extract modified raw preparation of
garlic-inhibited platelet aggregation by suppressing the influx
of calcium ions through their chelation within platelet cytosol
or by altering other intracellular second messengers within
the platelets [60].
A trial using AGE preparation of garlic recommended
dose-dependent inhibition of platelet aggregation, that is,
AGE inhibited platelet aggregation at dose of 7.2 gm however
fibrinolytic activity was inhibited at all doses among hypercholesterolemia patients [61]. A trial on ischemic heart disease
patients after using raw/fried garlic significantly increased
fibrinolytic activity [62].
A study using garlic oil as an ingredient reported two
important paraffinic polysulphides diallyl disulphide (DADS)
and diallyl trisulphide (DATS) mainly responsible for causing
antiplatelet inhibition. Action of DATS was found more
potent as compared to DADS; however, it was seen that
inhibition of platelet by DATS was reversible. The results of
this trial conclude that garlic oil should not be used in patients
with comorbid demanding necessary inhibition of platelets
activity [63].
When discussing its efficacy in comparison to statins, its
action was found comparable to compar to clopidogrel [64].
Similarly, it was also suggested that AGE preparation if taken
as a dietary supplement by healthy individuals may be beneficial in protection against cardiovascular disease through
inhibition of platelet aggregation [65].
All of the above results showed some beneficial effects;
however, two studies done by [66] Legnani et al. and [67]
Scharbert et al. on healthy individuals showed no effect on
fibrinolysis and platelet activity.
It is concluded that garlic inhibits platelet aggregation
by multiple mechanisms and may have a role in preventing
cardiovascular disease. However, data is scarce, and further
studies are required to prove this fact.
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14. Garlic Role on Endothelium and
Vascular Dilatation
Though garlic mainly protect against cardiovascular disease
through reduction of lipid levels, however few studies suggest that it has some effects on endothelium and vascular
dilatation through inhibition of oxidation process. Garlic
contains allicin as the main active ingredient with prospect to
provide beneficial effects on cardiovascular system. A study
by Chan et al. [68] showed that allicin caused enhancement
of antioxidant state by lowering of reactive oxygen species
and increasing the production of glutathione. Similarly, garlic
prevents from cardiovascular disease through inhibition of
LDL oxidation thus inhibiting atherosclerosis of vessels,
important risk factors for cardiovascular disease [69]. Budoff
in 2006 conducted a pilot study in which patients who were
already on statin therapy were given AGE extract of garlic and
placebo and their degree of coronary artery calcification was
assessed which slowed down in patient who were given Garlic
therapy plus statin as compared to the other group [70].
Garlic role in primary and secondary prevention of cardiac disease was also questionable as few trials done showed
positive results as demonstrated by Table 3. This fact was
tested among patients with cardiovascular disease by giving
garlic powder tablets allicor, and their 10-year prognostic
risk of acute myocardial infarction and sudden death were
assessed. It was seen that after 12-month treatment with
allicor, there was significant decrease of cardiovascular risk.
that is, 1.5 fold in men and 1.3 fold in women. The main influence that played a role in cardiovascular risk reduction was
the decrease in LDL cholesterol by 32.9 mg/dL in men and by
27.3 mg/dL in women, thus proving the fact that it has effective role in secondary cardiovascular disease prevention [71].

15. Side Effects of Garlic
A couple of case reports have published the adverse effects
of garlic ingestion, where one claimed allergic dermatitis
observed in a patient taking raw garlic [72]. Another stated
that the antithrombotic activity of garlic might interact with
oral anticoagulants; therefore, caution must be taken when
using in concordance with oral anticoagulants [73].

16. Conclusion
We conclude that the beneficial effect of garlic preparations
on lipids and blood pressure extends also to platelet function,
thus providing a wider potential protection of the cardiovascular system through its major effects on cholestrol reduction.
However, its efficacy in blood pressure reduction is mild
with some beneficial effects on platelet aggregation. This
warrants the need for more meta-analyses using standardized
preparations with a close watch on methodological shortfalls.
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